Akari Therapeutics (NASDAQ:AKTX) Earns Sell Rating from Analysts at StockNews.com
StockNews.com initiated coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Free Report) in a research report report published on Wednesday. The firm issued a sell rating on the biopharmaceutical company’s stock. Akari Therapeutics Stock Performance NASDAQ:AKTX opened at $1.31 on Wednesday. Akari Therapeutics has a 52 week low of $0.85 and a 52 week high […]
StockNews.com initiated coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Free Report) in a research report report published on Wednesday. The firm issued a sell rating on the biopharmaceutical company’s stock. Akari Therapeutics Stock Performance NASDAQ:AKTX opened at $1.31 on Wednesday. Akari Therapeutics has a 52 week low of $0.85 and a 52 week high […]
